Posts

September 2025 brought big shifts in thoracic oncology — from DLL3 bispecifics in ES-SCLC to new data reinforcing PACIFIC in stage III NSCLC, plus real-world survivorship insights. Here’s the key data you need this month.

The most practice-changing, promising, and watchlist data — distilled into 3 bullets each.

Ten lung cancer studies to have on your radar across ADCs, peri-op immunotherapy, EGFR with brain mets, and KRAS G12C combos — plus three embargoed heavy-hitters to unveil during plenaries.